XSHE
002642
Market cap695mUSD
Jul 10, Last price
6.84CNY
1D
-4.07%
1Q
-12.98%
Jan 2017
-65.94%
IPO
13.25%
Name
Ronglian Group Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ronglian Group Ltd., an international technology firm headquartered in Beijing, China, delivers a comprehensive suite of IT services and solutions. Established in 2001, the company was formerly known as UEC Group Ltd. Its core offerings encompass robust infrastructure and data center management, including strategic IT planning, seamless application and system integration, expert operation and maintenance, and bespoke specialized services. The company also specializes in virtualization, along with private and hybrid cloud deployments, extending to B2B, smart city initiatives, and operational service management. Furthermore, Ronglian provides advanced enterprise cloud services, covering everything from initial cloud architecture design and planning to efficient service migration, meticulous resource management, custom integration development, and continuous operational monitoring. It develops tailored industry-specific cloud platforms for sectors like insurance, exploration, and education. The group is also active in the Internet of Things (IoT) domain, establishing an Internet of Vehicles ecosystem through dedicated hardware, software, business platforms, and data analytics. Its Internet of Water solution focuses on managing leaks, optimizing ventilation, and safeguarding water quality. Comprehensive big data services, including storage, application development, and visualization, are also provided, alongside innovative smart news solutions. Moreover, Ronglian delivers bio-data platforms and biological cloud computing services, alongside comprehensive management solutions for hospitals and the broader healthcare sector. Its diverse clientele spans numerous sectors, including energy, transportation, telecommunications, media, finance, insurance, government, education, manufacturing, biotechnology, and healthcare.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||